Dasatinib - Bristol-Myers Squibb

Drug Profile

Dasatinib - Bristol-Myers Squibb

Alternative Names: BMS-354825; Sprycel

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Massachusetts General Hospital; Otsuka Pharmaceutical; Sarcoma Alliance for Research through Collaboration; University of Texas M. D. Anderson Cancer Center; Weill Cornell Medical College
  • Class Amides; Antineoplastics; Chlorobenzenes; Piperazines; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase III Prostate cancer
  • Phase II Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Myeloproliferative disorders; Sarcoma
  • Phase I/II Glioblastoma; Non-Hodgkin's lymphoma
  • No development reported Colorectal cancer; Leukaemia; Malignant melanoma; Mesothelioma; Multiple myeloma; Non-small cell lung cancer
  • Discontinued Pancreatic cancer; Scleroderma

Most Recent Events

  • 30 Aug 2018 Preregistration for Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, First-line therapy, In adolescents, In children, Newly diagnosed) in USA (PO) prior to August 2018
  • 30 Aug 2018 US FDA accepts sBLA for dasatinib for Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, First-line therapy, In adolescents, In children, Newly diagnosed) for review
  • 30 Aug 2018 US FDA assigns action date of 29/12/2018 for dasatinib for Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, First-line therapy, In adolescents, In children, Newly diagnosed) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top